The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / November / A Faster Route to Antibody Peptide Maps
Mass Spectrometry Clinical News and Research

A Faster Route to Antibody Peptide Maps

Researchers use direct-infusion mass spectrometry to analyze 96 antibody samples in about two hours

11/18/2026 2 min read
  • Full Article
  • Summary
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: A Faster Route to Antibody Peptide Maps

At a Glance

CategoryDetail
ConditionMonoclonal antibody peptide mapping and characterization
Key MechanismsRaPiD-mAb-MS combines 96-well sample preparation, automated nanoelectrospray direct infusion, high-resolution Orbitrap mass spectrometry, and software for peptide matching and modification analysis.
Target PopulationMonoclonal antibody researchers and development teams evaluating antibody sequences, modifications, formulations, or process conditions.
Care SettingAntibody discovery, formulation screening, and process development; regulated testing would require further method-specific qualification.

Key Highlights

  • The workflow processes 96 samples in approximately 1.5 to 2 hours; sample preparation takes about four hours.
  • Across more than 1,500 experiments involving 28 monoclonal antibody sequences, median sequence coverage was 100% and mean coverage was 97.7%.
  • The method detected oxidation, deamidation, glycosylation, terminal modifications, sequence variants, and antibody-drug conjugation sites.
  • Stable isotope-labeled peptides showed an average detection limit of approximately 0.7% relative abundance, varying from 0.2% to 1.2% by peptide.
  • The authors describe conventional LC-MS as important for ultratrace detection and established regulated quality-control workflows.

Guideline-Based Recommendations

Diagnosis

  • The article describes an analytical workflow for antibody peptide mapping, not a clinical diagnostic method.

Management

  • Use RaPiD-mAb-MS primarily for discovery, formulation screening, and process development, as positioned by the authors.
  • Retain conventional LC-MS for ultratrace detection and established regulated quality-control workflows.

Monitoring & Follow-up

  • The workflow can assess antibody sequence coverage and modifications including oxidation, deamidation, glycosylation, terminal modifications, sequence variants, and conjugation sites.
  • Oxidation measurements in forced-degradation studies correlated closely with conventional LC-MS results.

Risks

  • Detection sensitivity is lower than targeted LC-MS/MS can provide for some low-abundance species.
  • Deamidated peptides may overlap with unmodified counterparts and require high-resolution targeted MS/MS.
  • Isoaspartate is isobaric with aspartate and cannot be detected directly; the researchers used an optional enzymatic labeling step to create a measurable mass shift.
  • Further method-specific qualification is required before direct infusion can support regulated testing.

Patient & Prescribing Data

Not applicable; the article concerns laboratory analysis of monoclonal antibodies, not patient treatment.

No prescribing or treatment recommendations are reported.

Clinical Best Practices

  • Interpret detection limits in light of peptide-specific results, which ranged from 0.2% to 1.2% relative abundance.
  • Consider targeted MS/MS when deamidated and unmodified peptides overlap.
  • Use the optional enzymatic labeling step when assessing isoaspartate.
  • Do not assume the workflow is qualified for regulated testing; the authors state that further method-specific qualification is required.

Related Resources & Content

    This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

    Newsletters

    Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

    Newsletter Signup Image

    False

    Advertisement

    Recommended

    False

    Related Content

     This Week’s Mass Spec News
    Mass Spectrometry
    This Week’s Mass Spec News

    April 4, 2025

    2 min read

     What If Computers Could Smell?
    Mass Spectrometry
    What If Computers Could Smell?

    April 3, 2025

    13 min read

    Computers can “see” and “hear,” but fully digitizing scent has so far eluded science – but that may soon change

    The Analytical Scientist Innovation Awards 2024: #6
    Mass Spectrometry
    The Analytical Scientist Innovation Awards 2024: #6

    December 3, 2024

    3 min read

    Syft Technologies’ William Pelet introduces the Syft Explorer – the world's first fully mobile, real-time, and direct trace gas analyzer

    The Analytical Scientist Innovation Awards 2024: #4
    Mass Spectrometry
    The Analytical Scientist Innovation Awards 2024: #4

    December 5, 2024

    6 min read

    Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

    Affiliations:

    Specialties:

    Areas of Expertise:

    Contributions:

    False

    The Analytical Scientist
    Subscribe

    About

    • About Us
    • Work at Conexiant Europe
    • Terms and Conditions
    • Privacy Policy
    • Your Privacy Choices
    • Advertise With Us
    • Contact Us

    Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.